Regeneron Pharmaceuticals Inc. has identified multiple monoclonal antibodies that work against the highly infectious omicron variant and expects to begin testing them in humans this quarter.
The drugmaker has started discussions with regulators to establish a development plan, Chief Scientific Officer George Yancopoulos said Monday in an online presentation to the JPMorgan Healthcare Conference. The Tarrytown, New York-based drugmaker sells a Covid-19 antibody therapy called REGEN-COV, but its potency has diminished in the face of omicron.
